tetano
Editor, Senior Moderator
Heliyon
. 2021 Jul 10;7(7):e07548.
doi: 10.1016/j.heliyon.2021.e07548. eCollection 2021 Jul.
Recent advance of ACE2 and microbiota dysfunction in COVID-19 pathogenesis
Zhidan Yu[SUP] 1 [/SUP], Zhaojie Yang[SUP] 2 [/SUP], Yuesheng Wang[SUP] 1 [/SUP], Fang Zhou[SUP] 1 [/SUP], Suli Li[SUP] 1 [/SUP], Chan Li[SUP] 3 [/SUP], Lifeng Li[SUP] 1 [/SUP], Wancun Zhang[SUP] 1 [/SUP], Xiaoqin Li[SUP] 1 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the coronavirus disease 2019 (COVID-19) and has become the world's most pressing public health threat. Although not as common as respiratory symptoms, a substantial proportion of patients with COVID-19 presented the gastrointestinal symptoms. ACE2, as the receptor of SARS-CoV and SARS-CoV-2, is highly expressed in the epithelia of the epithelium cells in lung and intestine. In addition, ACE2 is essential for the innate immunity, amino acid transportation and the homeostasis of intestinal microecology. The composition of gut microbiota in COVID-19 patients was altered and concordant with inflammatory, which may explain the gastrointestinal symptoms in patients. Here we reviewed and discussed the evolving role for ACE2 and gut microbiota in SARS-CoV-2 infection which might provide innovative approaches to targeting ACE2 and gut microbiota for the COVID-19 therapy.
Keywords: Angiotensin-converting enzyme 2; Coronavirus disease 2019; Gut microbiota; Respiratory syndrome coronavirus 2.
. 2021 Jul 10;7(7):e07548.
doi: 10.1016/j.heliyon.2021.e07548. eCollection 2021 Jul.
Recent advance of ACE2 and microbiota dysfunction in COVID-19 pathogenesis
Zhidan Yu[SUP] 1 [/SUP], Zhaojie Yang[SUP] 2 [/SUP], Yuesheng Wang[SUP] 1 [/SUP], Fang Zhou[SUP] 1 [/SUP], Suli Li[SUP] 1 [/SUP], Chan Li[SUP] 3 [/SUP], Lifeng Li[SUP] 1 [/SUP], Wancun Zhang[SUP] 1 [/SUP], Xiaoqin Li[SUP] 1 [/SUP]
Affiliations
- PMID: 34296023
- PMCID: PMC8270732
- DOI: 10.1016/j.heliyon.2021.e07548
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the coronavirus disease 2019 (COVID-19) and has become the world's most pressing public health threat. Although not as common as respiratory symptoms, a substantial proportion of patients with COVID-19 presented the gastrointestinal symptoms. ACE2, as the receptor of SARS-CoV and SARS-CoV-2, is highly expressed in the epithelia of the epithelium cells in lung and intestine. In addition, ACE2 is essential for the innate immunity, amino acid transportation and the homeostasis of intestinal microecology. The composition of gut microbiota in COVID-19 patients was altered and concordant with inflammatory, which may explain the gastrointestinal symptoms in patients. Here we reviewed and discussed the evolving role for ACE2 and gut microbiota in SARS-CoV-2 infection which might provide innovative approaches to targeting ACE2 and gut microbiota for the COVID-19 therapy.
Keywords: Angiotensin-converting enzyme 2; Coronavirus disease 2019; Gut microbiota; Respiratory syndrome coronavirus 2.